IVA337 + Placebo + Empagliflozin
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NASH - Nonalcoholic Steatohepatitis
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Trial Timeline
Jun 29, 2022 → Jun 4, 2024
NCT ID
NCT05232071About IVA337 + Placebo + Empagliflozin
IVA337 + Placebo + Empagliflozin is a phase 2 stage product being developed by Inventiva for NASH - Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05232071. Target conditions include NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05232071 | Phase 2 | Completed |
Competing Products
20 competing products in NASH - Nonalcoholic Steatohepatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| AZD2693 | AstraZeneca | Phase 1 | 33 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 33 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Tropifexor (LJN452) + Cenicriviroc (CVC) | Novartis | Phase 2 | 52 |
| Tropifexor + Licogliflozin | Novartis | Phase 2 | 52 |
| LMB763 + Placebo | Novartis | Phase 2 | 52 |
| Tropifexor (LJN452) + Placebo | Novartis | Phase 2 | 52 |
| TRO19622 + Placebo | Roche | Phase 2 | 52 |
| SEL + SIM | Gilead Sciences | Phase 2 | 51 |
| Seladelpar + Placebos | Gilead Sciences | Phase 2 | 51 |
| Placebo + SIM | Gilead Sciences | Phase 2 | 51 |
| Cilofexor | Gilead Sciences | Phase 1 | 32 |
| Firsocostat + Fenofibrate | Gilead Sciences | Phase 1 | 32 |
| GS-9674 + Placebo to match GS-9674 | Gilead Sciences | Phase 2 | 51 |